Adoptive TIL therapy plus anti-PD1 in metastatic melanoma Adaptieve TIL therapie met anti-PD1 in gemetastaseerd melanoom

Trial Profile

Adoptive TIL therapy plus anti-PD1 in metastatic melanoma Adaptieve TIL therapie met anti-PD1 in gemetastaseerd melanoom

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs CAR T cell therapy Autolus (Primary) ; Interferon alpha (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms ACTME
  • Most Recent Events

    • 20 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top